Gregg Alton

Gregg Alton joined Corcept’s Board in March 2020 after serving twenty years as a senior executive at Gilead Sciences, Inc. From January 2019 until March 2019, Mr. Alton was Gilead’s interim Chief Executive Officer. Prior to that, he was the company’s Chief Patient Officer, responsible for Gilead’s government affairs, public affairs, patient outreach and engagement initiatives, as well as efforts to facilitate access to its medicines around the world. Mr. Alton also oversaw Gilead’s corporate and medical affairs functions, its digital patient solutions and patient-centered outcomes groups, and commercial operations in certain countries. Before that, he was the company’s General Counsel. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward, LLP, where he specialized in corporate finance transactions for healthcare and information technology companies. Mr. Alton is a member of the Board of Directors of Enochian Biosciences, the AIDS Institute, the Boys and Girls Clubs of Oakland, and the Partners in Health Board of Trustees. Mr. Alton received a bachelor’s degree in legal studies from the University of California at Berkeley and a law degree from Stanford University.